knowledge -WSS

knowledge

author：focus 2025-10-01 15:40:06 - browse：7696

Moderna chairman Noubar Afeyan exuded star power earlier this month as he commanded the spotlight at BIO 2023, the industry’s largest convention.

Basking in the accolades heaped on Moderna’s celebrated Covid-19 vaccine, Afeyan regaled the Boston audience with the company’s origin story and greeted fans who lined up to snap selfies with him. Stuart Cable, a partner in the law firm Goodwin who’s represented Moderna and joined Afeyan on stage, called Moderna “arguably the most successful story in the history of biotechnology.”

But the Cambridge, Mass.-based company can’t afford to rest on its laurels. Two and a half years after its vaccine liberated tens of millions from pandemic lockdowns — ringing up more than $36 billion in sales so far — Moderna faces a changing business and regulatory environment. Demand for Covid shots is waning, a backlash over drug prices is gaining traction, and questions about its next act loom.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： First recipient of genetically engineered pig kidney has died

explore

WSS

Readout LOUD podcast: What to know about H5N1 bird flu

IRA could hurt research into orphan drugs for rare diseases

New weight loss drugs vying to be the next Wegovy or Mounjaro

WATCH: Why do bright lights make us see spots?

First recipient of genetically engineered pig kidney has died

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

focus

knowledge

explore

Medical records are filled with copy

Readout LOUD podcast: What to know about H5N1 bird flu

Malaria cases in Florida and Texas: Here’s what you need to know

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

Walensky prepares to leave CDC — and Congress — behind

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Making AI in medicine accessible to smaller, and rural hospitals

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

IRA could hurt research into orphan drugs for rare diseases

hotspot

Popular nasal decongestant doesn't actually relieve congestion

PEPFAR is under serious threat — and so is global health

White House touts steps to stem shortages of cancer treatments

Bird flu outbreak in cows is latest avian flu curveball

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Popular nasal decongestant doesn't actually relieve congestion

knowledge

knowledge

explore

leisure time